Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +670.30% | +258.77% | -38.63% | -91.41% | -95.13% |
| Gross Profit Growth | +2277.11% | +206.28% | -29.12% | -89.76% | -94.26% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +147.14% | +91.41% | +98.55% | +81.68% | +17.34% |
| Weighted Average Shares Diluted Growth | +147.14% | +92.96% | +100.39% | +81.68% | +18.97% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -95.65% | -75.23% | -100.00% | +43.30% | -15.45% |
| Inventory Growth | +9.78% | -100.00% | -100.00% | -100.00% | -100.00% |
| Asset Growth | -34.08% | -62.46% | -68.54% | -78.86% | -81.45% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -24.26% | -2.13% | -66.48% | -10.05% | +20.46% |
| R&D Expense Growth | -34.70% | -39.72% | -78.07% | -93.37% | -99.19% |
| SG&A Expenses Growth | -9.13% | +3.26% | -33.40% | -61.86% | -60.83% |